The efficacy of the selective serotonin reuptake inhibitors for social anxiety disorder (social phobia): A meta-analysis of randomized controlled trials

International Clinical Psychopharmacology

Volumn 15, Issue SUPPL. 2, 2000, Pages

  Van der Linden, G J H ^a   Stein, D J ^a   Van Balkom, A J L M ^a  

^a STELLENBOSCH UNIVERSITY   (South Africa)

Author keywords

Cochrane; Meta analysis; Social anxiety disorder; Social phobia; SSRIs

Indexed keywords

ALPRAZOLAM; ATENOLOL; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUSPIRONE; CITALOPRAM; CLOMIPRAMINE; CLONAZEPAM; FLUOXETINE; FLUVOXAMINE; MONOAMINE OXIDASE INHIBITOR; PAROXETINE; PHENELZINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ANXIETY NEUROSIS; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; HUMAN; META ANALYSIS; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; RANDOMIZED CONTROLLED TRIAL; SOCIAL PHOBIA; TREATMENT OUTCOME;

EID: 0033736350     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-200008002-00004     Document Type: Conference Paper

References (68)

1. Paroxetine in social anxiety disorder. A randomised placebo-controlled study
2. Clomipramine and diazepam in the treatment of agoraphobia and social phobia in general practice
3. Diagnostic and Statistical Manual of Mental Disorders (DSM-III) 3rd edn
4. Diagnostic and Statistical Manual of Mental Disorders, 4th edn
5. On behalf of the Paroxetine Study Group (1999). A randomised, double-blind, placebo-controlled study of paroxetine in the treatment of social phobia/social anxiety disorder
6. Fluoxetine and social phobia (letter)
7. The Cochrane Collaboration. Preparing, maintaining and disseminating systematic reviews of the effects of health care
8. Fluoxetine for the treatment of social phobia
9. Use of the selective serotonin reuptake inhibitor citalopram in the treatment of generalized social phobia
10. Sertraline in social phobia
11. The brief social phobia scale
12. Treatment of social phobia with clonezepam and placebo
13. Pharmacotherapy of social anxiety disorder
14. Social phobia: The clinical efficacy and tolerability of the monoamine oxidase-A and serotonin uptake inhibitor brofaromine. A double-blind placebo-controlled study
15. Cognitive-behavioural and pharmacological treatments of social phobia: A controlled study
16. Cognitive behavioral group treatment for social phobia: Effectiveness at five-year follow-up
17. Moclobemide in social phobia: A double-blind, placebo-controlled clinical study
18. Social phobia; a clinical overview
19. Social phobia: Longitudinal course and long-term outcome of cognitive-behavioral treatment
20. Sertraline for social phobia: A double-blind, placebo-controlled crossover study
21. Venlafaxine in social phobia
22. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: Results from the National Comorbidity Survey
23. Citalopram in the treatment of social phobia: A report of three cases
24. Phenelzine vs imipramine in atypical depression: A preliminary report
25. Social phobia: A review of a neglected anxiety disorder
26. Social phobia
27. Pharmacotherapy of social phobia: An interim report of a placebo-controlled comparison of phenelzine and atenolol
28. Phenelzine vs atenolol in social phobia. A placebo-controlled comparison
29. Brofaromine for social phobia: A multicentre, placebo-controlled, double-blind study
30. Agoraphobia, simple phobia, and social phobia in the National Comorbidity Survey
31. Paroxetine in social phobia
32. The classification of phobic disorders
33. Different ages of onset in varieties of phobia
34. Sertraline in the treatment of patients with social phobia
35. A pilot study of buspirone in the treatment of social phobia
36. Sertraline in social phobia
37. Moclobemide in social phobia: A controlled dose-response trial
38. Treatment of social phobia with fluoxetine
39. Paroxetine efficacy in social phobia
40. Sertraline in the treatment of social phobia
41. Fluoxetine in social phobia
42. Social phobia: Comorbidity and morbidity in an epidemiologic sample
43. Buspirone in social phobia
44. Functional impairment in social phobia
45. A placebo-controlled trial of moclobemide in social phobia
46. Psychotherapy in the overall management strategy for social anxiety disorder
47. The measurement of disability
48. Paroxetine in the treatment of generalized social phobia: Open-label treatment and double-blind placebo-controlled discontinuation
49. Paroxetine treatment of generalised social phobia (social anxiety disorder)
50. Fluvoxamine treatment of social phobia (social anxiety disorder): A double-blind, placebo-controlled study
51. Fluoxetine treatment of social phobia
52. Fluoxetine efficacy in social phobia
53. Meta-analysis of cognitive-behavioral treatments for social phobia
54. Social phobia: A comparison of behavior therapy and atenolol
55. A study of the clinical effects of phenelzine and placebo in the treatment of phobia anxiety
56. Fluoxetine efficacy in social phobia
57. Sertraline in social phobia
58. Pharmacotherapy for social phobia: A systematic review of randomised controlled trials (Protocol for a Cochrane Review)
59. Psychopharmacological treatment of social phobia: Clinical and biochemical effects of brofaromine, a selective MAO-A inhibitor
60. Psychopharmacological treatment of social phobia: A double blind placebo controlled study with fluvoxamine
61. Clinical effects of buspirone in social phobia: A double-blind placebo-controlled study
62. Tranylcypromine in social phobia
63. Pharmacotherapy of social phobia. A controlled study with moclobemide and phenelzine
64. Social phobia in general health care: An unrecognised undertreated disabling disorder
65. The impact of social phobia on quality of life